Vertex SVP sells shares under 10b5-1 plan

Vertex Pharmaceuticals senior executive Kristen Ambrose reported two stock transactions.

Rhea-AI Filing Summary

Vertex Pharmaceuticals senior executive Kristen Ambrose reported two stock transactions. As SVP & Chief Accounting Officer, she sold 223 shares of Vertex common stock in an open-market sale at an average price of $486.35 per share under a company-approved Rule 10b5-1 trading plan.

She also disposed of 546 shares at $485.11 per share to cover tax obligations by delivering shares rather than cash. After these transactions, she directly held 6,981 shares of Vertex common stock.

Insider Trade Summary

Net Seller: 223 shares

Net Sell 2 txns

Insider Ambrose Kristen

Role SVP & Chief Accounting Officer

Sold 223 shs ($108K)

Type	Security	Shares	Price	Value
Sale	Common Stock	223	$486.35	$108K
Exercise Price or Tax Liability	Common Stock	546	$485.11	$265K

Holdings After Transaction: Common Stock — 6,981 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share transactions did Kristen Ambrose report at VRTX?

Kristen Ambrose reported two transactions in Vertex common stock. She sold 223 shares in an open-market trade and disposed of 546 shares to cover tax liabilities by delivering shares instead of cash, both at prices around $485 per share.

How many Vertex (VRTX) shares did Kristen Ambrose sell in the open market?

She sold 223 shares of Vertex common stock in an open-market transaction. The reported average sale price was $486.35 per share, and the transaction was executed under a company-approved Rule 10b5-1 trading plan.

Why were 546 Vertex (VRTX) shares disposed of in Kristen Ambrose’s Form 4?

The 546 shares were disposed of to satisfy tax liabilities by delivering stock. This tax-withholding disposition used an average price of $485.11 per share, rather than a discretionary open-market sale for investment purposes.

How many Vertex (VRTX) shares does Kristen Ambrose own after these transactions?

Following the reported transactions, Kristen Ambrose directly owns 6,981 shares of Vertex common stock. This figure reflects her holdings after both the 223-share open-market sale and the 546-share tax-withholding disposition.

Was Kristen Ambrose’s Vertex (VRTX) share sale pre-planned?

Yes. The filing notes the transaction was made under a company-approved trading plan pursuant to Rule 10b5-1. Such plans pre-schedule sales, helping executives diversify holdings while reducing concerns over trading on nonpublic information.

What is Kristen Ambrose’s role at Vertex (VRTX) mentioned in the Form 4?

Kristen Ambrose is identified as Vertex’s Senior Vice President and Chief Accounting Officer. As an executive officer, her direct holdings and transactions in Vertex common stock must be reported publicly on Form 4 under insider reporting rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 05:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ambrose Kristen

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		F		546	D	$485.11	7,204	D
Common Stock	02/25/2026		S(1)		223	D	$486.35	6,981	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.